Six out of ten of the sclerosis patients who are not in disease-modifying treatment do not attend annual follow-ups. This means that the patients do not receive the symptom management or rehabilitation they need. These results come from a new study by ApHER conducted in collaboration with the Danish Multiple Sclerosis Society, presented by Prof. Anders Green [...]
A poorly regulated diabetes patient is costly for both the public healthcare system and the private insurance companies. In a recent cost-effectiveness study of the LIVA platform ApHER concludes that there is a desirable investment return by managing diabetes patients digitally through online lifestyle coaching. Read the article at LIVA Healthcare here.
Randomized studies of SLGT-2 inhibitors and GLP-1 receptor agonists are now followed-up by register studies. And scientists are eagerly presenting real life data these years. This makes professor Anders Green to point out that scientists need to remember openness towards each others' methodological schools. Read the article from Medicinsk Tidsskrift here.
Denmark is a world champion in register studies which has also provided invaluable knowledge in diabetes research. However, legal back-and-forthing can cost us the leading place, experts warn. Read the article at Medicinsk Tidsskrift here.
Professor Anders Green gave an invited presentation on the epidemiological results from the Diabetes Impact Study in connection with the Annual Meeting of the Scandinavian Society for the Study of Diabetes, held the 19th-21st of May in Nyborg (Denmark).
The Nordic countries Denmark, Finland, Norway and Sweden have many cross-national similarities regarding political systems and universal tax-financed healthcare systems with full population coverage, but different utilization patterns of Finansteride have been observed in a new study. Link to publication.
The newest publication of the Diabetes Impact Study reveals the dramatic forecasts of the diabetes epidemic. Today, 380,000 Danes have diabetes and this number will increase to 650,000 in 2015 and further 1.2 million people in 2040 according to the forecasts. The costs of diabetes in Denmark amounts up to almost 32 billion DKK every year, [...]
On August 20th 2015, APEHR presented the results of the Diabetes Impact Study 2013 together with the Danish Diabetes Association at a press conference. Among other interesting findings, the study showed that the diabetes-related costs of type 1 and type 2 diabetes in Denmark were 31.8 billion DKK/4.8 billion EUR in 2011, furthermore, the attributable costs [...]
In cooperation wih the University of Southern Denmark, APEHR has just published an article as part of the Danish Diabetes Impact Study 2013, where we present trends in the incidence, morbidity, mortality, and prevalence of diabetes in Denmark for the period 2000 through 2011. Link to publication.
With the Danish parliament in front, Denmark is preparing on becoming the internationally leading country in register- and database research within the health field. Professor and epidemiological scientist, Anders Green, is one of the architects behind the standardized platform on the future clinical cancer databases and tells his perspective on new ways within cancer treatment in Magasinet [...]